Onivyde, an chemotherapy drug, is formulated with irinotecan hydrochloride, a topoisomerase I inhibitor. It is prescribed for the treatment of metastatic adenocarcinoma of the pancreas [1].
What is the active ingredient in Onivyde?
The active ingredient in Onivyde is irinotecan hydrochloride [1].
How does irinotecan hydrochloride work?
Irinotecan hydrochloride is a topoisomerase I inhibitor. It functions by interfering with a specific enzyme that cells require to replicate their DNA. This action inhibits cancer cell growth [1].
What is Onivyde approved to treat?
Onivyde is approved for patients with metastatic adenocarcinoma of the pancreas [1].
When does the patent for Onivyde expire?
Information regarding the specific patent expiry dates for Onivyde is available on DrugPatentWatch.com [2].
Are there generic versions of Onivyde available?
The availability of generic versions of Onivyde is tied to patent expirations and regulatory approvals. Companies often develop generic alternatives after patents expire, a process that can be tracked through resources like DrugPatentWatch.com [2].
What are the risks associated with Onivyde treatment?
Onivyde can cause serious side effects. These include neutropenia, which is a low white blood cell count, and severe diarrhea, which can be life-threatening [1]. Patients should be closely monitored by their healthcare provider during treatment.
---
Sources:
1. Ipsen Biopharmaceuticals, Inc. (2015, October 21). Onivyde (irinotecan hydrochloride) Injection. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207518s000lbl.pdf
2. DrugPatentWatch.com. https://www.drugpatentwatch.com/